Camblong Jurgi sold $138K of SOPH
Camblong Jurgi (Executive Chairman) sold 20,000 shares of SOPHiA GENETICS SA (SOPH) at $6.92 ($0.14M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the reported open-market sale by the executive chairman, including trade size, price, and that it was under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale, but the 10b5-1 designation and lack of fundamental updates suggest limited incremental trading edge.
What to watch
The disclosure does not indicate whether the sale was part of a larger scheduled program, nor does it provide any fundamental change; the net holdings after sale remain substantial (3,472,822 shares).
Background
The article is an SEC Form 4 insider transaction filing for SOPHiA GENETICS SA.
Ticker impact
SOPHiA GENETICS executive chairman Camblong Jurgi sold 20,000 shares on 2026-08-04 under a 10b5-1 plan, worth $138,412.
Likely limited near-term impact; any reaction should be muted given the stated 10b5-1 pre-arranged plan.
Form 4 reports an open-market sale with a pre-arranged 10b5-1 plan; the filing provides no new company fundamentals, guidance, or regulatory/contract event.
Market effects
No clear sector read-through from a single disclosed 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially if it coincides with other negative signals not mentioned here.
Key entities
- issuerSOPHiA GENETICS SA
Company whose insider transaction is disclosed on SEC Form 4.
- insiderCamblong Jurgi
Executive Chairman and director who sold shares under a 10b5-1 plan.
